Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.34 |
| ▸ | GLRA3 | O75311 | 2/20 | 0.34 |
| ▸ | GLRB | P48167 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12256800 | 1.00 | ALDH1A1 (0.37) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL2369647 | 1.00 | ALDH1A1 (0.37) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL25346532 | 1.00 | ALDH1A1 (0.37) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL12256886 | 0.89 | ALDH1A1 (0.36) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL2376489 | 0.88 | FURIN (0.37) | ALDH1A1SLC6A2SLC6A4SLC6A3SCD | |
| SCHEMBL2380142 | 0.88 | FURIN (0.37) | ALDH1A1SLC6A2SLC6A4SLC6A3SCD | |
| SCHEMBL2376497 | 0.88 | FURIN (0.37) | ALDH1A1SLC6A2SLC6A4SLC6A3SCD | |
| SCHEMBL2376487 | 0.88 | FURIN (0.37) | ALDH1A1SLC6A2SLC6A4SLC6A3SCD | |
| SCHEMBL2380146 | 0.88 | FURIN (0.37) | ALDH1A1SLC6A2SLC6A4SLC6A3SCD | |
| SCHEMBL2379911 | 0.87 | ALDH1A1 (0.37) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539345-B1 | 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-8754079-B2 | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| EP-2539345-A1 | 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO]THIENO [2, 3 - D]PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-02 | — | — | EP | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| WO-2011104334-A1 | 4 - [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2, 3 - D] PYRIMIDINES HAVING MNKL/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, UCK2 | ALDH1A1 4123/4885CYP3A4 3020/4885TDP1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.